Erythropoietin-driven Signalling and Cell Migration Mediated by PolyADP-ribosylation

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Sep 8

PMID 22955851

Citations 7

Authors

D Inbar

M Cohen-Armon

D Neumann

Affiliations

Soon will be listed here.

Abstract

Background: Recombinant human erythropoietin (EPO) is the leading biotechnology engineered hormone for treatment of anaemia associated with chronic conditions including kidney failure and cancer. The finding of EPO receptors on cancer cells has raised the concern that in addition to its action in erythropoiesis, EPO may promote tumour cell growth. We questioned whether EPO-induced signalling and consequent malignant cell manifestation is mediated by polyADP-ribosylation.

Methods: Erythropoietin-mediated PARP (polyADP-ribose polymerase-1) activation, gene expression and core histone H4 acetylation were examined in UT7 cells, using western blot analysis, RT-PCR and immunofluorescence. Erythropoietin-driven migration of the human breast epithelial cell line MDA-MB-435 was determined by the scratch assay and in migration chambers.

Results: We have found that EPO treatment induced PARP activation. Moreover, EPO-driven c-fos and Egr-1 gene expression as well as histone H4 acetylation were mediated via polyADP-ribosylation. Erythropoietin-induced cell migration was blocked by the PARP inhibitor, ABT-888, indicating an essential role for polyADP-ribosylation in this process.

Conclusions: We have identified a novel pathway by which EPO-induced gene expression and breast cancer cell migration are regulated by polyADP-ribosylation. This study introduces new possibilities regarding EPO treatment for cancer-associated anaemia where combining systemic EPO treatment with targeted administration of PARP inhibitors to the tumour may allow safe treatment with EPO, minimising its possible undesirable proliferative effects on the tumour.

Citing Articles

PARP-1 genetic polymorphism associated with radiation sensitivity of non-small cell lung cancer.

Wang H, Xie H, Wang S, Zhao J, Gao Y, Chen J Pathol Oncol Res. 2023; 28:1610751.

PMID: 36590386 PMC: 9795517. DOI: 10.3389/pore.2022.1610751.

Implications of the Essential Role of Small Molecule Ligand Binding Pockets in Protein-Protein Interactions.

Skolnick J, Zhou H J Phys Chem B. 2022; 126(36):6853-6867.

PMID: 36044742 PMC: 9484464. DOI: 10.1021/acs.jpcb.2c04525.

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.

Cohen-Armon M Cancers (Basel). 2020; 12(6).

PMID: 32575437 PMC: 7352794. DOI: 10.3390/cancers12061628.

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.

Fratangelo F, Camerlingo R, Carriero M, Pirozzi G, Palmieri G, Gentilcore G Int J Oncol. 2018; 53(3):1149-1159.

PMID: 29956724 PMC: 6065454. DOI: 10.3892/ijo.2018.4457.

Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology.

Schaefer L, Tredup C, Gubbiotti M, Iozzo R FEBS J. 2016; 284(1):10-26.

PMID: 27860287 PMC: 5226885. DOI: 10.1111/febs.13963.

References

Wang S, Wang H, Davis B, Liang J, Cui R, Chen S . PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun. 2011; 412(2):379-84. PMC: 3163691. DOI: 10.1016/j.bbrc.2011.07.107. View

Mengozzi M, Cervellini I, Villa P, Erbayraktar Z, Gokmen N, Yilmaz O . Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc Natl Acad Sci U S A. 2012; 109(24):9617-22. PMC: 3386063. DOI: 10.1073/pnas.1200554109. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Cohen-Armon M . PARP-1 activation in the ERK signaling pathway. Trends Pharmacol Sci. 2007; 28(11):556-60. DOI: 10.1016/j.tips.2007.08.005. View

Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D . Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol. 2008; 46(4):713-21. DOI: 10.1016/j.molimm.2008.10.004. View

Fu P, Jiang X, Arcasoy M . Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun. 2009; 379(3):696-701. PMC: 2666149. DOI: 10.1016/j.bbrc.2008.12.146. View

Kohno M, Tanimura S, Ozaki K . Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull. 2011; 34(12):1781-4. DOI: 10.1248/bpb.34.1781. View

Lester R, Jo M, Campana W, Gonias S . Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 2005; 280(47):39273-7. DOI: 10.1074/jbc.M509446200. View

Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas Jr F, Tabira T . Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993; 268(15):11208-16. View

10.

Brines M, Cerami A . Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006; 70(2):246-50. DOI: 10.1038/sj.ki.5001546. View

11.

Zheng Y, Xu X, Peng F, Yu J, Wu H . The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells. Oncol Rep. 2011; 25(5):1399-405. DOI: 10.3892/or.2011.1212. View

12.

Schreiber V, Dantzer F, Ame J, de Murcia G . Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7(7):517-28. DOI: 10.1038/nrm1963. View

13.

Poulikakos P, Solit D . Resistance to MEK inhibitors: should we co-target upstream?. Sci Signal. 2011; 4(166):pe16. DOI: 10.1126/scisignal.2001948. View

14.

Lombardero M, Kovacs K, Scheithauer B . Erythropoietin: a hormone with multiple functions. Pathobiology. 2011; 78(1):41-53. DOI: 10.1159/000322975. View

15.

Javle M, Curtin N . The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol. 2011; 3(6):257-67. PMC: 3210467. DOI: 10.1177/1758834011417039. View

16.

Banerjee S, Kaye S . The role of targeted therapy in ovarian cancer. Eur J Cancer. 2011; 47 Suppl 3:S116-30. DOI: 10.1016/S0959-8049(11)70155-1. View

17.

Rios J, Puhalla S . PARP inhibitors in breast cancer: BRCA and beyond. Oncology (Williston Park). 2011; 25(11):1014-25. View

18.

Tentori L, Lacal P, Muzi A, Dorio A, Leonetti C, Scarsella M . Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer. 2007; 43(14):2124-33. DOI: 10.1016/j.ejca.2007.07.010. View

19.

Cheng R, Feng D, Zheng H, Tan Y . [Effect of activation of p-MAPK on activating c-fos and c-jun proteins in breast cancer]. Hunan Yi Ke Da Xue Xue Bao. 2003; 26(1):10-2. View

20.

Witthuhn B, Quelle F, Silvennoinen O, Yi T, Tang B, Miura O . JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993; 74(2):227-36. DOI: 10.1016/0092-8674(93)90414-l. View